Sun Pharmaceutical, Zydus Lifesciences and Oriental Rail Infrastructure to see some action today

19 Mar 2025 Evaluate

Sun Pharmaceutical Industries’ subsidiary -- TARO Pharmaceuticals Inc. has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Earlier, TARO Pharmaceuticals Inc. had entered into an agreement with Antibe Therapeutics Inc., Canada, pursuant to which Sun Pharma had agreed to acquire 100% stake in Antibe Therapeutics Inc.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg). Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. Apalutamide tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Oriental Rail Infrastructure has secured order worth Rs 1.89 crore from Integral Coach Factory (ICF), Chennai, Indian Railways for Supply and Installation of 18 sets of One Coach Set of Seats (with fixing arrgt) for Second AC Chair Car coaches.

GR Infraprojects has received Letter of Acceptance (LoA) from National Highways Authority of India (NHAI) (Ministry of Road, Transport & Highways) for Construction of Agra - Gwalior Greenfield Road. The NHAI Estimated Project Cost is Rs 4262.78 crore and the project is to be completed within 910 days from Appointed date.

Magnum Ventures has raised Rs 15 crore through the allotment of 1,500 Listed, Rated, Secured, Redeemable, Non-Convertible Debentures (NCD) (Tranche-II), of the face value of Rs 1,00,000 on a private placement basis. The Debt Raise Committee of the Company has at its meeting held on March 18, 2025, allotted the same.

Premier Explosives has received an export order for Rs 18.90 crore for supply of Defence Explosives to be delivered within a period of 5 months.

NTPC has planned to issue unsecured non-convertible debentures (NCDs) of Rs 4,000 crore on March 20, 2025, through private placement at a coupon of 7.26% p.a. for a tenor of 15 years, maturing on March 20, 2040, under the board resolution dated June 29, 2024 and subsequent approval obtained through shareholders’ resolution dated August 29, 2024. This is the first issue of debentures under the above mentioned approval. Proceeds will be utilized for, inter alia, funding of capital expenditure, refinancing of existing loans and other general corporate purposes. The debentures are proposed to be listed on NSE.

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.